As the director of Global Science Initiatives, James A. Hendrix, Ph.D., leads key efforts to advance the science agenda of the Alzheimer’s Association, a worldwide leader in advancing the field of Alzheimer’s research. Drawing from more than 20 years of pharmaceutical and biotech industry experience, Dr. Hendrix oversees Association initiatives that convene leaders from science and industry to develop, expand and increase the success rate of Alzheimer’s diagnostic tools and drugs to treat and prevent the disease. 

Dr. Hendrix manages the Alzheimer’s Association Research Roundtable, a platform that enables international scientific, industry and government leaders to work together to overcome shared obstacles in Alzheimer’s science and drug development. His role also includes management of the Global Biomarker Standardization Consortium (GBSC), an initiative that unites key researchers and clinicians with industry, regulatory and government leaders to achieve consensus on the best ways to standardize and validate biomarker tests, such as blood tests and brain scans, for use in clinical practices worldwide. 

Dr. Hendrix is the Association’s lead contact for the $100 million Imaging Dementia-Evidence for Amyloid Scanning (IDEAS) Study. IDEAS is assessing the impact of brain amyloid PET imaging on health and medical outcomes for people with cognitive impairment, such as proper counseling on safety and future planning, and access to more appropriate drugs.

As an Association spokesperson, Dr. Hendrix has been interviewed by numerous international media outlets, including TIME magazine and TIME.com, The Washington Post, Bloomberg News Service, Newsweek, Scientific American, BBC News and NPR.

Dr. Hendrix holds a Ph.D. in chemistry from Colorado State University. He spent more than 20 years at Sanofi-Aventis and predecessor companies, where he led research for central nervous system drug development.